# Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

> **NCT03894969** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 541 (actual)

## Conditions studied

- Respiratory Disorders

## Interventions

- **BIOLOGICAL:** GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
- **BIOLOGICAL:** Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)

## Key facts

- **NCT ID:** NCT03894969
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-23
- **Primary completion:** 2020-08-31
- **Final completion:** 2021-08-13
- **Target enrollment:** 541 (ACTUAL)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03894969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03894969, "Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03894969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*